A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Th
This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumabwhen given in combination with trastuzumab emtansine compared with placebo andtrastuzumab emtansine for patients with residual invasive HER2-positive breast cancerfollowing neoadjuvant taxane-based and HER2-targeted therapy including trastuzumab, whoare at high risk of disease recurrence. The primary endpoint for this study is invasivedisease-free survival (IDFS).
Breast cancer survivor clinical trial offers recovery and hope
Lindsay Fry is a breast cancer survivor who was first diagnosed in 2019. Her treatment regimen of surgery, radiation and chemotherapy began in fall 2019. Shortly after completing her treatment, Fry became the first participant in a new clinical trial at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) that aims to help breast cancer survivors regain their energy and remain cancer free.
Shortening Adjuvant PHoton IRradiation (SAPHIRe): A Randomized Trial of Hypofractionated Versus Conventionally Fractionated Regional Nodal Irradiation for Invasive Breast Cancer (CTMS# 23-0020)
To compare how often cancer recurs (comes back) after 3 weeks of radiation compared to 5 weeks of radiation in patients who receive radiation therapy delivered to the lymph nodes near the breast. The side effects that can develop during or after radiation treatment, including how often arm swelling (edema) happens, will also be studied
S1207, Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer (CTRC# 13-0002)
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet know whether hormone therapy is more effective when given with or without everolimus in treating breast cancer. PURPOSE: This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer.
Mays Cancer Center hosts annual breast cancer symposium, addresses care and advancements in treatment
Mays Cancer Center at UT Health San Antonio, in partnership with the American Association for Cancer Research (AACR), is hosting the 46th annual San Antonio Breast Cancer Symposium (SABCS) at the Henry B. Gonzalez Convention Center on Dec. 5-9. This scientific and education symposium, initiated and owned by Mays Cancer Center, is the world’s largest […]
How genetic testing could determine your risk of getting breast cancer
Natalie Poullard, MA, MS, CGC, a certified genetic counselor at Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, provides a brief understanding of genetic testing benefits, the types of tests available and what you can expect during an appointment. Watch here